Image
Date de parution
Sommaire ou résumé
Patrick Alexandre, CEO of Crossject, said: ‘‘We are proud to announce a sound commercial agreement for ZENEO® Hydrocortisone in the US and Canada with an American leader in Adrenal Insufficiency. Eton has successfully established strong relations with the patient communities and medical specialists that are its core focus. ZENEO® Hydrocortisone answers a medical need. This strong partnership will contribute to saving lives by bringing to patients and their families a modern autoinjection possibility.’’
PDF du document